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Abstract: In addition to genetic changes, post-transcriptional events strongly contribute to the
progression of malignant tumors. The RNA-binding protein HuR (ELAVL1) is able to bind and
stabilize a large group of target mRNAs, which contain AU-rich elements (ARE) in their 3′-untranslated
region. We found HuR to be upregulated in malignant melanoma in vitro and in vivo, significantly
correlating with progression in vivo. Additionally, we could show that miR-194-5p can regulate
HuR expression level. HuR knockdown in melanoma cells led to the suppression of proliferation
and the induction of cellular senescence. Interestingly, HuR overexpression was sufficient to
inhibit senescence in BRAFV600E-expressing melanocytes and to force their growth. Here, MITF
(Microphthalmia-associated transcription factor), a key player in suppressing senescence and an
ARE containing transcript, is positively regulated by HuR. Our results show for the first time that
the overexpression of HuR is an important part of the regulatory pathway in the development of
malignant melanoma and functions as a switch to overcome oncogene-induced senescence and
to support melanoma formation. These newly defined alterations may provide possibilities for
innovative therapeutic approaches.
Keywords: malignant melanoma; HuR; oncogene induced senescence; MITF;
Microphthalmia-associated transcription factor
1. Introduction
Until a few decades ago, malignant melanoma was a rather rare tumor disease. There is hardly
any other tumor entity, in which incidence rates rise as fast as those for melanoma in recent years [1].
Since the development of immune checkpoint blockade and BRAF inhibition approaches, melanoma
therapy has changed [2]. However, even though these approaches show efficacy in many patients,
more than half of the patients have to face the consequences of inefficient cancer therapy and therapy
resistance [3]. Furthermore, many patients show no response at all. Therefore, a better understanding
of the development and progression of melanoma is essential.
An important player in both the development and progression of melanoma is the constitutive
activation of MAPK signaling. Approximately 60% of melanomas carry an oncogenic BRAF mutation,
with BRAFV600E being the most prevalent [4,5]. Interestingly, not only many melanomas but also
approximately 80% of melanocytic nevi harbor such a mutation, however, alone not being sufficient
for melanoma development [6,7]. In melanocytes, oncogenic BRAF signaling induces a cell cycle arrest
known as oncogene-induced senescence (OIS) [8], which acts as a safeguard mechanism to prevent
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tumor development. Understanding the mechanisms of development and overcoming senescence will
lead to a better knowledge of melanoma formation.
Senescence, a condition found in post-mitotic cells, serves as a protective stress response that
limits the replication of aged, damaged, or neoplastic cells [9] via a stable cell cycle arrest in the
G0/G1-phase with simultaneously maintained metabolic activity. By chromosomal condensation,
senescent cells commonly form senescence-associated heterochromatic foci (SAHF), which can lead
to a stable downregulation of many pro-proliferative genes and thereby to a growth arrest [10].
The senescent phenotype of cells is highly heterogeneous, resulting in the use of multiple markers to
analyze senescence.
The dysregulation of post-transcriptional processes is an important factor in the progression
of malignant tumors. RNA binding proteins (RBPs) are able to influence every step of transcript
processing, including splicing, translation, and change of localization and stability. In doing so, RBPs
can both act as stabilizing (e.g., ELAVL proteins) or destabilizing (e.g., AUF1 and TTP) molecules,
resulting in the complex regulation of transcripts [11]. An important key element in RBP mode of
action are adenine-uridine-rich elements (ARE), commonly found in the 3′ untranslated region (UTR)
of mRNAs [12,13]. These elements are defined as regions with a high frequency of adenine and
uridine bases. Via these ARE motives, RBPs can fine-tune mRNA stability as a response to extra- and
intracellular stimuli. ARE-containing transcripts often occur in short-lived transcripts of early response
genes like cytokines, cell cycle regulators, and proto-oncogenes [12].
The ubiquitously expressed ARE-binding protein HuR belongs to the mammalian Hu/ELAV
family of RNA binding proteins (RBPs) and was first described in Drosophila as elav (embryonic lethal,
abnormal vision). The human HuR/ELAVL1 gene is located on chromosome 19p13.2 and encodes
a 32 kDa protein containing the three highly conserved RNA-binding domains RPM-1, RPM-2 and
RPM-3. RPM-3 is responsible for binding to the poly(A) tail in the 3′-untranslated region (UTR) of
target mRNAs, whereas RPM-1 and RPM-2 bind to AU-rich elements (ARE) in these 3′UTRs. Via
this interaction, HuR is known to stabilize target mRNAs [14]. With many targets being mRNAs
that encode for proteins important for cell growth, angiogenesis, tumorigenesis, and metastasis, HuR
overexpression is known to correlate with poor prognosis in some cancer types [15–17]. In malignant
melanoma, HuR is discussed as a prognostic marker [18]. However, little is known about the importance
of HuR in the development and progression of this cancer type.
In this study, we were able to prove that HuR not only holds a pro-tumorigenic function in
melanoma but also bears the capacity to break oncogene-induced senescence in melanocytes via,
amongst others, upregulation of MITF and thereby might be involved in the development of melanoma.
2. Results
2.1. ARE Containing mRNAs Are More Abundant in Melanoma Cells Compared to NHEMs
Initially, we analyzed changes in the mRNA level of transcripts in different melanoma cell lines
(primary tumor (PT): Mel Ho, A375; metastasis (Met): 501 Mel, Lu 1205) compared to normal human
epidermal melanocytes (NHEMs). We calculated mRNA expression values of 28,536 genes in NHEMs
and primary and metastatic melanoma cells based on cDNA array data (GEO: GSE108969) [19].
In comparison to expression values in NHEMs (mean of values set 1), we found more genes to be
upregulated than downregulated in melanoma cell lines with the mean values of PT/NHEMs and
Met/NHEMs > 2-fold (Figure S1).
In general, apart from elevated transcription, high transcript levels were mainly the result of
changed mRNA stability. One of the most common determinants of RNA stability in mammalian
cells are AU-rich elements (AREs). An alignment of the cDNA array data with a list of all
ARE-containing transcripts (http://brp.kfshrc.edu.sa/ARED/; 3 November 2019) revealed that the
number of transcripts containing 3′UTR ARE-sequences was significantly upregulated compared to
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those without ARE-sequences (Figure 1A). Bearing intronic ARE-sequences did not correlate with the
mRNA levels of the corresponding transcripts.
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Figure 1. HuR (ELAVL1) expression in malignant melanoma in vivo and in vitro. (A) Mean expression 
of mRNAs in primary melanoma cells related to expression in NHEM cells. No = mRNAs without 
ARE binding sequence (n = 9993); iARE = mRNAs with ≥1 intronic ARE sequence (n = 5560); ARE = 
mRNAs with ≥ 1 ARE sequence in the 3′UTR (n = 2095). (B) Relative expression of HuR mRNA in 
NHEMs and melanoma cell lines, mRNA level in NHEMs is set 1. (C) Correlation of HuR expression, 
and the mean expression of 150 randomly chosen ARE containing mRNAs in 10 different melanoma 
cell lines. (D) Densitometric quantification (left) and exemplary image (right) of Western blot analysis 
of HuR protein levels in primary and metastatic melanoma cell lines compared to NHEMs. HuR 
Figure 1. HuR (ELAVL1) expression in malignant melanoma in vivo and in vitro. (A) Mean expression
of mRNAs in primary melanoma cells related to expression in NHEM cells. No = mRNAs without ARE
binding sequence (n = 9993); iARE = mRNAs with ≥1 intronic ARE sequence (n = 5560); ARE = mRNAs
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with ≥ 1 ARE sequence in the 3′UTR (n = 2095). (B) Relative expression of HuR mRNA in NHEMs
and melanoma cell lines, mRNA level in NHEMs is set 1. (C) Correlation of HuR expression, and the
mean expression of 150 randomly chosen ARE containing mRNAs in 10 different melanoma cell lines.
(D) Densitometric quantification (left) and exemplary image (right) of Western blot analysis of HuR
protein levels in primary and metastatic melanoma cell lines compared to NHEMs. HuR protein level
in NHEMs is set 1. (E) Relative expression of HuR mRNA in normal skin (n = 7) and melanoma tissue
(n = 45) of patients. HuR mRNA level in normal skin is set 1. (F) Representative immunohistochemical
staining of HuR protein in primary human melanoma and metastatic melanoma tissue samples (4
shown, n = 10; for quantification see Figure 3). (G) Survival analysis in a skin cutaneous melanoma
(SKCM) patient dataset comparing low and high HuR (ELAVL1) levels (lower percentile: 80, higher
percentile: 20). *A p-value of <0.05 was considered statistically significant. The uncropped blots and
molecular weight markers of Figure 1D are shown in Figure S5.
2.2. HuR (ELAVL1) Is Upregulated in Malignant Melanoma In Vitro and In Vivo
Focusing on the relevance of ARE containing transcripts, we observed the RNA binding protein
(RBP) HuR to be dysregulated in melanoma cells. The primary (Mel Ho and A375) and metastatic
melanoma (501 Mel and Lu 1205) cell lines showed a significant upregulation of HuR mRNA compared
to NHEMs (Figure 1B) in the cDNA array data. Correspondingly, we were able to prove a significant
correlation between the average expression levels of 150 randomly chosen ARE-genes (Table S1) with the
HuR mRNA levels in 10 different melanoma cell lines (Mel Ho, A375, 501 Mel, Lu 1205, WM3211, Sbcl2,
WM793, WM1366, WM1158, WM9) (Figure 1C). As an RBP that positively regulates ARE-containing
transcripts, we chose to investigate HuR and its influence on malignant melanoma further.
To assess HuR protein levels, we screened lysates of NHEMs, primary melanoma (Mel Juso,
Mel Wei, and Mel Ho), and metastatic melanoma cell lines (Mel Im, SkMel28, HTZ19). The protein
expression was significantly upregulated (Figure 1D) in all melanoma cell lines compared to NHEMs.
Interestingly, HuR mRNA and protein expression were most abundant in cell lines derived from
melanoma metastases (Figure 1B,D). Supporting the in vitro results, data obtained from GEO profiles
showed an in vivo upregulation of HuR mRNA in malignant melanoma patient tissue samples (n = 45)
compared to normal skin samples (n = 7) (data set GDS1375/201727_s_at) (Figure 1E). Besides this data
set, additional GEO profiles data sets were found to support this result (GDS1989/201726_at, data not
shown). In vivo analysis of HuR protein expression by immunohistochemical staining in primary and
metastatic tumor tissue showed HuR expression in all tissue samples, with high expression levels in
primary and even higher in metastatic tissues (Figure 1F). By using OncoLnc (http://www.oncolnc.org;
2019/11/03) we analyzed survival data obtained from The Cancer Genome Atlas (TCGA) project with
expression data from a human skin cutaneous melanoma (SKCM) data set. Here, we were able to show
that an elevated level of HuR significantly correlates with lower overall survival of melanoma patients
(Figure 1G).
2.3. The Loss of miR-194-5p Expression in Melanoma Promotes the Upregulation of HuR
HuR is known to be regulated on post-transcriptional levels [20–23]. We screened for microRNAs
bearing binding sites in the 3′UTR of the HuR mRNA, which was downregulated in malignant
melanoma. One miRNA identified in this search was miR-194-5p (Figure 2A), which was almost lost in
malignant melanoma cells (PT: Mel Juso, Mel Wei, Mel Ho; Met: Mel Im, SkMel28, HTZ19) compared
to NHEMs (Figure 2B). Mimic transfection of this microRNA of melanoma cell lines Mel Wei and
Mel Im led to a significant decrease in the activity of a HuR3′UTR luciferase construct (Figure 2C).
Accordingly, the overexpression of miR-194-mimic led to reduced HuR protein level (Figure 2D) in
both cell lines.
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Figure 2. Regulation of HuR (ELAVL1) expression by miR-194-5p. (A) MiR-194-5p binding site in the 
3′UTR of ELAVL1 mRNA. (B) MiR-194-5p expression levels in primary and metastatic melanoma cell 
lines compared to NHEMs. (C) Luciferase HuR 3′UTR-reporter activity in siCtrl and miR-194-5p-
mimic transfected melanoma cells. Activity in siCtrl transfected cells is set 1. (D) Densitometric 
quantification (right) and exemplary image (left) of Western blot analysis of HuR protein levels in 
siCtrl and miR-194-5p-mimic transfected melanoma cells. HuR protein level in siCtrl transfected cells 
is set 1. *A p-value of <0.05 was considered statistically significant. The uncropped blots and molecular 
weight markers of Figure 2D are shown in Figure S6. 
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Further, we analyzed the localization of HuR in melanoma cell lines and in melanocytes. Here, 
we performed fractionation of cell lysates of NHEM, Mel Wei, and Mel Im cells into nucleus and 
cytoplasmic fractions. We analyzed these fractions by Western blot analysis and observed strong 
nuclear localization of HuR in both melanoma cell lines. Additionally, we observed cytoplasmic 
localization in both melanoma cell lines but not in NHEMs (Figure 3A). By immunofluorescence 
staining with an anti-HuR antibody very low or no nuclear HuR staining was detected in NHEM. In 
agreement with data discussed in Figure 1, we observed a higher expression of HuR in Mel Wei 
compared to NHEM cells. In the metastatic cell line Mel Im, the expression was found to be 
upregulated even further (Figure 3B,C). Not just the expression but also the localization changed with 
progression, showing cytoplasmic localization in melanoma cell lines, with Mel Im presenting higher 
cytoplasmic levels than Mel Wei (Figure 3B,D). In vivo, localization was changed in metastatic 
compared to primary tumor tissue. In primary melanoma tissue, immunohistochemical staining of 
HuR was observed in the nuclei of the cells and rarely in the cytoplasm. In metastatic tumor tissue 
we observed more cytoplasmic staining compared to primary tumors (Figure 3E). 
Figure 2. Regulation of HuR (ELAVL1) expression by miR-194-5p. (A) MiR-194-5p binding site in the
3′UTR of ELAVL1 mRNA. (B) MiR-194-5p expression levels in primary and metastatic melanoma cell
lines compared to NHEMs. (C) Luciferase HuR 3′UTR-reporter activity in siCtrl and miR-194-5p-mimic
transfected melanoma cells. Activity in siCtrl transfected cells is set 1. (D) Densitometric quantification
(right) and exemplary image (left) of Western blot analysis of HuR protein levels in siCtrl and
miR-194-5p-mimic transfected melanoma cells. HuR protein level in siCtrl transfected cells is set 1. *A
p-value of <0.05 was considered statistically significant. The uncropped blots and molecular weight
markers of Figure 2D are shown in Figure S6.
2.4. uR Expression and Localization Changes in the Progression of MM In Vitro and In Vivo
Further, we analyzed the localization of HuR in melanoma cell lines and in melanocytes. ere,
we performed fractionation of cell lysates of NHE , el ei, and Mel Im cells into nucleus and
cytoplas ic fractions. l t s fr cti s estern blot analysis and observed strong
nuclear localization of HuR in both melanoma cell lines. Additionally, we observed cytoplasmic
localization in both melano a cell lines but not in NHEMs (Figure 3A). By immunofluorescence
staining it ti- ti r lo or no nuclear HuR staining was d tected in NHEM.
In agreement with d ta discussed in Figure 1, we observed a i her r ssi f i el ei
compared to NHEM cells. In the metastatic cell line Mel Im, th expression was found to be upregulated
even furth r (Figure 3B,C). Not just the expression but also the localization changed with progr ssion,
showing cytoplasmic localization in melanoma cell lines, with Mel Im presenting high r cytoplasmic
levels than Mel Wei (Figure 3B,D). In vivo, localization was changed in metastati compared to prim ry
tumor tissue. In primary melanoma tissue, immunohistochemical staining of HuR w s observed
in the nuclei of the cells and rarely in the cytoplasm. In metastatic tumor tissu we observed more
cytoplasmic staining compared to primary tumors (Figure 3E).
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Figure 3. Changes of HuR expression and localization in the progression of MM in vitro. (A) 
Fractionation of cell lysates of NHEM, Mel Wei, and Mel Im cells in nucleus and cytoplasm fraction 
and subsequent Western blot analysis of HuR protein. Histone H3 served as a nucleus control, 
GAPDH and β-actin as cytoplasm controls. Representative pictures shown. (B) Representative 
immunofluorescence pictures of NHEM, Mel Wei, and Mel Im cells stained with DAPI (blue) and 
HuR (red). (C) Percentage of no, low, medium, or high HuR level in IF-staining in NHEM, Mel Wei, 
and Mel Im cells. Significant comparisons with NHEMs were marked with *, significant comparisons 
between Mel Wei and Mel Im with ‘. (D) Percentage of only nuclear/low cytoplasmic and high 
cytoplasmic HuR level in IF-staining in Mel Wei and Mel Im cells. (E) Percentage of only 
nuclear/nuclear and cytoplasmic HuR localization in IH-staining of primary tumor and metastasis 
melanoma tissue samples (see Figure 1F). *A p-value of <0.05 was considered statistically significant. 
The uncropped blots and molecular weight markers of Figure 3A are shown in Figure S7. 
Figure 3. Changes of HuR expression and localization in the progression of MM in vitro.
(A) Fractionation of cell lysates of NHEM, Mel Wei, and Mel Im cells in nucleus and cytoplasm
fraction and subsequent Western blot analysis of HuR protein. Histone H3 served as a nucleus
control, GAPDH and β-actin as cytoplasm controls. Representative pictures shown. (B) Representative
immunofluorescence pictures of NHEM, Mel Wei, and Mel Im cells stained with DAPI (blue) and HuR
(red). (C) Percentage of no, low, medium, or high HuR level in IF-staining in NHEM, Mel Wei, and Mel
Im cells. Significant comparisons with NHEMs were marked with *, significant comparisons between
Mel Wei and Mel Im with ‘. (D) Percentage of only nuclear/low cytoplasmic and high cytoplasmic
HuR level in IF-staining in Mel Wei and Mel Im cells. (E) Percentage of only nuclear/nuclear and
cytoplasmic HuR localization in IH-staining of primary tumor and metastasis melanoma tissue samples
(see Figure 1F). *A p-value of <0.05 was considered statistically significant. The uncropped blots and
molecular weight markers of Fig re 3A are shown in Figure S7.
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2.5. The Knockdown of HuR Leads to Decreased Proliferative Capacity of Melanoma Cells In Vitro
To further unravel the role of increased HuR expression in melanoma cells, we next analyzed the
functional impact of HuR suppression in melanoma cells using a siPool specifically targeting HuR
(Figure S2A). The effect of HuR knockdown on the proliferation of Mel Wei and Mel Im melanoma
cells was determined using the xCELLigence real-time cell analysis (RTCA) system. HuR knockdown
(KD) showed an inhibitory effect on the growth of both cell lines (Figure 4A). With an XTT assay, we
were able to confirm these findings (Figure S2B). In a clonogenic assay, the ability of cells to form
colonies from single cells was analyzed. After HuR KD, no effect on the clonogenicity of both cell
lines was observed, as transfected cells showed the same colony number as the control cells. However,
HuR suppression led to smaller colonies in both cell lines (Figure 4B). This finding further emphasizes
the effect of HuR knockdown on the proliferation of melanoma cells and shows that the proliferative
effects in the preceding assays did not reflect cell death. Additionally, PI/Annexin staining of cells
showed no significant changes in apoptosis after siHuR (Figure S2C). We further analyzed the cell
cycle by flow cytometry and revealed an increase of siHuR transfected Mel Wei and Mel Im cells in the
G1/G0 phase compared to control cells hinting to a G1/G0 cell cycle arrest after HuR KD (Figure 4C).
On a molecular level, we observed a reduction in the activity of the pro-proliferative transcription
factor AP-1 (Figure 4D). Additionally, we were able to show that Cyclin D1 protein, a factor important
for G1/S transition, is downregulated in siHuR transfected melanoma cells (Figure 4E). These data
indicated that loss of HuR results in reduced cell proliferation by induction of a G1/G0 cell cycle arrest.
2.6. HuR Knockdown Induces Senescence Characteristics in Human Melanoma Cells
Strikingly, after knockdown of HuR, the melanoma cell lines developed morphological alterations
reminiscent of senescent cells, such as enlarged cell bodies and partially branched cellular extensions
(Figure S3A). To investigate whether the cell cycle arrest of Mel Wei and Mel Im melanoma cells after
the suppression of HuR is based on induction of senescence, we performed senescence-associated
(SA)-β-galactosidase staining. Interestingly, the SA-β-galactosidase staining was strongly induced
after HuR knockdown in both cell lines compared to control cells (Figure 5A), suggesting a strong
formation of a senescence-like phenotype under HuR suppression. Since it is well known that etoposide
induces premature senescence [24], etoposide was used as a positive control (Figure S3B). Senescent
cells often show the formation of so-called senescence-associated heterochromatin foci (SAHF). These
SAHF are formed by chromatin restructuring and commonly lead to the stable downregulation of
pro-proliferative genes and to cell cycle arrest. The promyelocytic leukemia protein (PML), a protein
functionally implicated in cellular senescence in melanoma, is involved in the development of these
SAHF [25,26]. SiHuR-transfected melanoma cells showed a strong increase in PML accumulation
(Figure 5B). Histon-deacetylases and –methyltransferases are also involved in the chromosomal
condensation and thereby formation of SAHF. Trimethylated histone 3 can be used as a marker
for hypermethylation [10,27]. Immunofluorescence staining showed a significant upregulation of
tri-methylated H3K9 in HuR suppressed melanoma cells (Figure S3C), further proving an induction
of senescence.
The induction of senescence by HuR suppression was in line with an MITFlow phenotype in these
cells (Figure 5C). MITF, known to negatively impact the program of senescence itself, contains ARE
sequences in its 3′UTR, suggesting an effect of HuR in MITF mRNA stabilization.
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clonogenic assays of Mel Wei and Mel Im cells (left panel) and quantification of colony number and 
size (right panel) in these cells (siCtrl = 1). (C) FACS-based cell cycle analysis of Mel Wei and Mel Im 
cells. Depicted are representative overlays of cell cycle histograms (left panel) and percentages of G1 
cell cycle fractions (right panel) in these cells (siCtrl = 1). (D) Luciferase AP-1-reporter activity in siCtrl 
and siHuR transfected melanoma cells (siCtrl = 1). (E) Densitometric quantification (right) and 
exemplary image (left) of Western blot analysis of Cyclin D1 protein levels in transfected Mel Wei and 
Mel Im cells (siCtrl = 1). *A p-value of <0.05 was considered statistically significant.  The uncropped 
blots and molecular weight markers of Figure 4E are shown in Figure S8. 
Figure 4. Influence of HuR knockdown on the proliferative capacity of melanoma cells in vitro.
(A) Exemplary real-time cell proliferation curves of Mel Wei and Mel Im cells (left panel) and quantified
‘slope’ (proliferative ability, siCtrl = 1) (right panel). (B) Exemplary images of anchorage-dependent
clonogenic assays of Mel Wei and Mel Im cells (left panel) and quantification of colony number and size
(right panel) in these cells (siCtrl = 1). (C) FACS-based cell cycle analysis of Mel Wei and Mel Im cells.
Depicted are representative overlays of cell cycle histograms (left panel) and percentages of G1 cell
cycle fractions (right panel) in these cells (siCtrl = 1). (D) Luciferase AP-1-reporter activity in siCtrl and
siHuR transfected melanoma cells (siCtrl = 1). (E) Densitometric quantification (right) and exemplary
image (left) of Western blot analysis of Cyclin D1 protein levels in transfected Mel Wei and Mel Im
cells (siCtrl = 1). *A p-value of <0.05 was considered statistically significant. The uncropped blots and
molecular weight markers of Figure 4E are shown in Figure S8.
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Figure 5. Influence of a HuR knockdown on senescence characteristics in melanoma cells. (A) Exemplary
images of light microscopic examination of SA-β-galactosidase staining in Mel Wei and Mel Im cells
(left). The percentages of SA-β-galactosidase positive cells (blue) were calculated (right) (siCtrl = 1).
(B) Exemplary images of PML immunofluorescence staining of Mel Wei and Mel Im cell lines. Panels
show overlays of PML (red) and DAPI (blue) staining (left). The graph shows the nuclear accumulation
of PML (right) (siCtrl = 1). (C) Densitometric quantification (right) and exemplary image (left) of
Western blot analysis of MITF protein levels in transfected Mel Wei and Mel Im cells (siCtrl = 1).
*A p-value of <0.05 was considered statistically significant. The uncropped blots and molecular weight
markers of Figure 5C are shown in Figure S9.
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2.7. HuR Overexpression in NHEM BRAFV600E Cells Is Capable to Bypass Oncogene Induced Senescence by
Induction of an MITFhigh Phenotype
The loss of HuR appears to be a driving force for senescence induction in malignant melanoma.
To understand whether the induction of HuR expression alone is able to overcome senescence in
HuRlow cells, we analyzed overexpression of HuR in the oncogene-induced senescence (OIS) model
NHEM BRAFV600E [8] by lentiviral overexpression (OE) of HuR in NHEM BRAFV600E and NHEM Mock
cells (Figure S4A,B). Lentiviral overexpression of HuR led to reduced SA-β-galactosidase staining in
NHEM BRAFV600E cells (Figure 6A). Additionally, increased HuR expression was capable of reversing
the induction of PML (Figure 6B) and tri-methylated H3K9 (Figure S4D) in NHEM BRAFV600E cells.
By immunofluorescence staining of the proliferation marker Ki-67 (Figure 6C) and by assessing the
cell numbers 1 week after transduction of the cells (Figure S4D), we were able to show that HuR
overexpression is capable of reversing the anti-proliferative effect of BRAFV600E OIS in NHEM cells.
Interestingly, we could not detect any changes in the HuR mRNA (Figure 7A) or protein (Figure 7B)
level in NHEM BRAFV600E compared to NHEM Mock cells, proving that HuR is not involved in OIS
in NHEM.
By overcoming OIS, melanoma can develop from melanocytic nevi. Interestingly, in RNA-seq
analysis of nevi (n = 23) and melanoma (derived from nevi, n = 57) tissue samples [28] we found
HuR to be significantly upregulated in nevi-derived melanomas compared to nevi, further suggesting
an effect of HuR induction in overcoming of OIS and melanoma induction (Figure 7C). By Western
blot analysis, we could show that HuR OE led to an upregulation of MITF mRNA and thereby to a
MITFhigh phenotype in NHEM BRAFV600E cells (Figure 7D).
In line with these data, we propose that HuR functions as a potential stabilizer of MITF, thereby
influencing the proliferation and the senescent phenotype of cells. With this capacity, HuR is sufficient to
bypass or potentially overcome OIS in melanocytes and could thereby be involved in the development
of nevi-derived melanoma (Schematic summary Figure 7E).
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immunofluorescence staining of NHEM Mock, NHEM BrafV600E, and NHEM BrafV600E/HuR OE cells 
(red) and DAPI (blue) staining. CopGFP served as a transduction control (green) (left). The graph 
shows the nuclear accumulation of PML (Mock = 1) (right). For better recognition, colors are only 
shown in the overlay, not in single pictures. (C Exemplary images of Ki-67 immunofluorescence 
staining of NHEM Mock, NHEM BrafV600E, and NHEM BrafV600E/HuR OE cells (red) and DAPI (blue) 
staining. CopGFP served as a transduction control (green) (top). The graph shows the accumulation 
of Ki-67 (Mock = 1) (bottom left). For better recognition, colors are only shown in the overlay, not in 
single pictures. *A p-value of <0.05 was considered statistically significant. 
Figure 6. HuR overexpression leads to a reduction of senescence characteristics in NHEM BrafV600E
cells. (A) Exemplary images of light microscopic examination of SA-β-galactosidase staining in
NHEM Mock, NHEM BrafV600E, and NHEM BrafV600E/HuR OE cells (left). The p rcentages of
SA-β-galactosidase positive cells (blue) were calculated (right) (Mock = 1). (B) Exemplary images of
PML i munofluorescence staining of NHE Mock, NHEM BrafV600E, and NHEM BrafV600E/HuR OE
cells (red) and DAPI (blue) staining. CopGFP served as a transduction control (green) (left). The graph
shows the nuclear accumulation of PML (Mock = 1) (right). For better recognition, colors are only
shown in the overlay, not in single pictures. (C Exemplary images of Ki-67 immunofluorescence
staining of NHEM Mock, NHEM BrafV600E, and NHEM BrafV600E/HuR OE cells (red) and DAPI (blue)
staining. CopGFP served as a transduction control (green) (top). The graph shows the accumulation
of Ki-67 (Mock = 1) (bottom left). For better recognition, colors are only shown in the overlay, not in
single pictures. *A p-value of <0.05 was considered statistically significant.
Cancers 2020, 12, 1299 12 of 22
Cancers 2020, 12, x FOR PEER REVIEW 12 of 22 
Figure 7. HuR overexpression leads to MITFhigh phenotype NHEM BrafV600E cells. (A) Relative 
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the development and progression of different cancer types, such as breast, lung, ovarian, and colon
cancer [31,32]. An important group of RBPs, ARE-binding proteins, bind to AU-rich elements in
target mRNAs. As a general phenomenon in melanoma, we found many stabilized mRNAs harboring
ARE-sequences. Usually, ARE-elements lead to rapid mRNA degradation. However, the expression
of HuR, a stabilizing ARE BP, was revealed to be induced in melanoma in vivo and in vitro, thereby
potentially stabilizing the targeted mRNAs. HuR transcript levels correlated with the number of
transcripts in melanoma cells, additionally indicating an important role of HuR in the induction of
ARE containing mRNAs.
Little is known about the abundance and impact of HuR in melanoma cells. It was shown before
that HuR is expressed in melanoma cell lines and that it is localized both in the nucleus and cytoplasm
of these cells [33]. However, this study was conducted without referring to melanocytes as ‘healthy’
melanoma precursor cells, therefore, not stating deregulation. Our data showed that in melanocytes,
HuR expression was absent or very low, and if expressed, mainly nucleic. In the melanoma cell lines,
we observed an upregulation of protein expression and a shift to the cytoplasm. In brain tumor
and non-small cell lung carcinoma cells, HuB (ELAVL2), the only neural ELAVL protein found to
be expressed in cancer cells, was shown to initiate the cytoplasmic translocation of HuR. Afterward,
HuB and HuR form a complex in the cytoplasm to enable the stabilization of ARE transcripts by
HuR [34]. HuB mRNA is upregulated in primary and metastatic melanoma cell lines compared to
NHEMs (GEO: GSE108969) [19]. This opens the possibility that HuB is responsible for the elevated
cytoplasmic expression of HuR, and the changed ARE mRNA stability that we found in the analyzed
melanoma cell lines.
Research on other diseases suggests that the localization of HuR is of major importance for the
function of this RBP. In studies on cobalamin metabolism disorders, the nucleocytoplasmic transport
of HuR was shown to be disrupted as a result of dephosphorylation and hypomethylation of HuR,
leading to decreased expression of genes involved in the cellular stress response, cell cycle regulation,
neurogenesis, and neuroplasticity [35]. In a zebrafish model, changed phosphorylation of HuR led
to the disruption of translocation and thereby to less stable gata1 mRNA and impaired formation of
red blood cells [36]. Interestingly, high cytoplasmic localization of HuR is known to correlate with
bad prognosis in several cancer types, including breast and lung [15,37] and now also in melanoma.
The enhanced cytoplasmic localization of HuR in metastasis compared to the primary tumor was
not discussed in the literature before—it might further promote tumor progression by prolonging
mRNA stability.
The dysregulation of RBPs is often the result of epigenetic events or microRNA-dependent
regulation [20,38]. Our in silico analyses identified a miR-194 binding site in the 3′UTR of the HuR
transcript, and miR-194 was proven to function as a tumor suppressor microRNA, found to be almost
lost in melanoma cell lines. Overexpression of a miR-194-specific mimic directly repressed HuR
expression in the melanoma cell lines proving a regulatory function. Some microRNAs are already
known to influence HuR in different cancer types. MiR-519, miR-125a, and miR-16 are known to
repress HuR protein expression in a direct manner [20,22,39]. The miR-29a regulates HuR indirectly by
the degradation of tristetraprolin (TTP) mRNA, an RBP negatively influencing HuR expression [23].
In melanoma, miR-29a expression is induced [40], whereas miR-125a and miR-16 get lost during
melanoma development [41,42]. This leads to the assumption that these miRNAs could be additionally
involved in the regulation of HuR in melanoma. There is no study about the regulation and function
of miR-519 in melanoma, yet.
Our functional analysis showed that suppression of endogenous HuR in melanoma cell lines
inhibited cell proliferation by inducing a G1 cell cycle arrest. In line, we identified the transcription
factor AP-1 and its target Cyclin D1, both shown to be affected by HuR in other cancer types, as targets
of HuR regulation in melanoma cells. Previously, it has been shown that HuR stabilizes WNT5A and
thereby positively influences melanoma cell migration [33]. Additionally, COX-2 mRNA was described
as a target of HuR stabilization, leading to a HuR dependent inhibition of apoptosis in melanoma
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cell lines [43]. In other cancer types, HuR is characterized as a stabilizer of cyclin mRNAs, thereby
promoting the proliferation of cancer cells [44,45]. In cervical cancer cells, the mRNA stability of Cyclin
D1 is increased by HuR overexpression [46]. In breast cancer, AP-1 expression is induced by increased
c-Jun mRNA stabilization as a result of HuR overexpression [47]. In some cases, HuR overexpression
in cancer cells seems to be beneficial for therapeutic approaches. Just recently, it was demonstrated
that drug-induced overexpression of HuR prevents the development of resistance to BRAFi therapy in
melanoma [48].
Detailed analyses of the G1 cell cycle arrest led us to focus on the mechanism of cellular senescence.
In the melanoma cell lines used in this study, knockdown of HuR led to the induction of senescence
with a change of cell morphology and the induction of several senescence markers. HuR was previously
shown to get lost during replicative senescence in human fibroblasts, resulting in a downregulation
of many proliferative genes [45]. Further, the loss of HuR expression during replicative senescence
was shown to enhance TIN2 protein expression and thereby the production of reactive oxygen species
(ROS), which further induce senescence [49].
This study shows for the first time that MITF, a master regulator in melanocyte differentiation and
pigmentation, is regulated by HuR. Melanoma cells with high cellular MITF-level are proliferative,
those with low levels show a stem cell-like invasive phenotype [50]. In addition, the long-term
reduction of MITF in melanoma cells leads to the induction of cellular senescence [51,52]. HuR
knockdown in the melanoma cell lines led to the suppression of MITF levels and to the induction
of senescence. It is not yet known whether MITF is regulated by HuR in a direct or indirect matter,
however, it is known that MITF bears an ARE sequence in its mRNA.
In all functional analyses, there was no significant difference detectable between the primary
melanoma cell line Mel Wei and the metastasis melanoma cell line Mel Im, leading to the assumption
that HuR does not change its function during progression. Induced expression in metastasis may
further enhance the expression of proliferative genes and accelerate proliferation.
The impact of HuR during the development of melanoma might be most important.
For nevi-derived melanomas, the hurdling of senescence is a crucial step in cancer development.
To address the question of whether HuR not just inhibits the formation of senescence in melanoma
but could also bypass a senescent phenotype in nevi, this study investigated for the first time the
influence of HuR on oncogene-induced senescence (OIS) in melanocytes. In our study, we observed
that the lentiviral induction of HuR in NHEM BRAFV600E enhanced the proliferative capacity and
lead to a revision of the senescent state of NHEM. Additionally, HuR overexpression in senescent
melanocytes led to the induction of MITF expression and to a more proliferative state. Additionally, we
were able to show a significant upregulation of HuR in nevi-derived melanomas, compared to healthy
nevi tissue. Melanocytic nevi arise after oncogene activation by hyperproliferation of melanocytes,
where the initial strong proliferation is stopped by the induction of senescence [8,53]. Revision of this
senescent state by additional mutations can lead to the formation of malignant melanoma. The capacity
of HuR to negatively influence OIS in senescent melanocytes and the upregulated expression of
HuR in nevi-derived melanomas suggests HuR to be an important player in the development of
malignant melanoma from benign nevi. In normal fibroblasts, the downregulation of HuR during DNA
damage-associated senescence has been shown to lead to inhibition of the heat shock transcription
factor Hsf1 via downregulation of SIRT1. The loss of Hsf1 downregulates the heat shock response of
cells, leaves cells unprotected against proteotoxic stresses, and thereby contributes to the maintenance
of cellular senescence [54]. Wang et al. were able to show that HuR is involved in the regulation
of several genes whose expression decreases during fibroblast senescence. Overexpression of HuR
in senescent fibroblasts restored a “younger” phenotype in the cells, while the reduction of HuR
expression further supported the senescent phenotype [45].
In summary, this study shows that a high expression of HuR in melanoma leads to higher
proliferation and inhibition of senescence. In BRAFV600E-transduced melanocytes, HuR overexpression
leads to the loss of senescence characteristics and a proliferative phenotype. The influence of HuR on
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the induction of proliferation in senescent melanocytes suggests an important impact of HuR on the
development of melanoma from melanocytic nevi. MITF, regulated by HuR, was found to be a player
in HuR-mediated inhibition of senescence.
Investigation of the molecular mechanisms of HuR regulation could help to identify new targets
for melanoma therapy. Currently, inhibition of cytoplasmic accumulation of HuR or disruption of
the interaction between HuR and its targets by small molecule inhibitors have been evaluated [55,56].
In colon carcinoma cells, the inhibitor MS-444 was shown to inhibit the tumorigenic potential of HuR,
without exerting a considerable effect on healthy intestinal cells [57,58]. Since the translocation of
HuR into the cytoplasm is a crucial factor in the pro-tumorigenic activity of HuR, the use of inhibitors
like MS-444 could offer a promising approach in melanoma therapy. However, the fact that ARE
mRNAs can also be regulated by other RBPs and microRNAs makes it difficult to understand the
regulation of ARE-containing transcripts and their contributions to cancer development, progression,
and therapeutic response. A thorough understanding of the interplay between RBPs, microRNAs, and
their targets could be the key in the development of new therapeutic approaches for the treatment
of melanoma.
Concluding, our findings indicate that the changed expression and subcellular localization of
HuR in melanoma is of particular importance for the enhanced proliferation and aggressiveness of
melanoma cells. Much more importantly, we found HuR to be a potential key player in the hurdling of
senescence and thereby the development of malignant melanoma.
4. Material and Methods
4.1. Cell Lines and Cell Culture Conditions
The human melanoma cell lines Mel Wei, Mel Ho (derived from primary cutaneous melanoma),
Mel Im, SkMel28, and HTZ19 (isolated from metastases of malignant melanoma) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with penicillin (400 U/mL), streptomycin
(50 µg/mL), and 10% fetal calf serum (all from Sigma-Aldrich, München, Germany). For the primary
melanoma cell line Mel Juso, RPMI-1640 (Roswell Park Memorial Institute) medium with NaHCO3 with
the same supplements was used. Normal human epidermal melanocytes (NHEMs) were cultivated
in MGM-4 BulletKit medium (Lonza, Basel, Switzerland). All cell lines were incubated at 37 ◦C in a
humidified atmosphere containing 8% (melanoma cell lines) or 5% (NHEMs) CO2. The cultivation of
all cell lines was described previously [59].
4.2. Lentiviral Transduction
Lentiviral transduction was performed as described previously [60]. BRAFV600E and
HuR overexpression (OE) plasmids were used, transductions were performed simultaneously.
As a control the copGFP plasmid (Mock) was used. For the preparation of the HuR OE
plasmid (pCDH-CMV-HuR-EF1-copGFP) we used a GFP-HuR plasmid as the HuR sequence
template and the lentiviral pCDH-CMV-MCS-EF1-copGFP (copGFP) vector as the target
vector. The primers 5′-CAGGAATTCAAGTCTAATGGTTATGAAGACC-3′ (HuR_w/oGFP_Fwd) and
5′-CAGGCGGCCGCTTATTTGTGGGACTTGTTGGTT-3′ (HuR_w/oGFP_Rev) were used to amplify
the HuR sequence, add correct restriction sites, and rebuild the start codon. GFP-HuR was a gift from
Christine Mayr (Addgene plasmid #121162; http://n2t.net/addgene:121162; RRID:Addgene_121162) [61].
4.3. siRNA Transfection
The melanoma cell lines Mel Wei and Mel Im were transfected with a siPool (about 30 siRNAs)
against HuR (functionally verified by siTOOLs Biotech, Planegg/Martinsried, Germany [62]) or
a negative control siPool using Lipofectamine RNAiMAX reagent (Life Technologies, Darmstadt,
Germany) as described previously [19]. For transfection, 150,000 cells were seeded into the wells of a
6-well plate. Cells were incubated for 72 h.
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4.4. miRNA Mimic Transfection
The melanoma cell lines Mel Wei and Mel Im were transfected with a microRNA-194-5p mimic
(Qiagen, Hilden, Germany) using Lipofectamine RNAiMAX reagent (Life Technologies) as described
previously [19]. For transfection, 150,000 cells were seeded into the wells of a 6-well plate. Cells were
incubated for 72 h. Allstars Negative Control siRNA (Qiagen) was used as a negative control.
4.5. mRNA + miRNA Expression Analysis
Isolation of total cellular RNA from cultured cells and generation of cDNAs by reverse transcription
(RT) reaction was performed as described previously [63]. Quantitative real-time PCR (qRT-PCR)
analysis of gene expression was performed on a LightCycler 480 system with specific sets of primers
(β-Aktin: 5’-CTACGTCGCCCTGGACTTCGAGC-3′, 5′-GATGGAGCCGCCGATCCACACGG-3′;
HuR: 5′-TAAGGTGTCGTATGCTCGCC-3′, 5′-CGGATAAACGCAACCCCTCT-3′) as described
previously [64].
Isolation of total cellular miRNA from cultured cells and generation of micDNAs by reverse
transcription (RT) reaction was performed as described previously [65]. For expression analysis of
microRNA-194, qRT-PCR was performed as described previously [66] using miScript microRNA-194
(or control U6) and universal primer (Qiagen, Hilden, Germany).
4.6. Subcellular Fractionation
For separation of nuclear and cytoplasmic cell fractions using centrifugation methods, the
subcellular fractionation protocol of Abcam (Cambridge, England) was used. Histone H3 was used as
a nuclear control, GAPDH and β-actin were used as cytoplasmic controls (List of primary antibodies:
Table S2).
4.7. Western Blotting
Preparation of complete cell lysates and Western blot analysis was performed as described
previously [67]. In brief, 10–30 µg of RIPA (Roche Diagnostics, Penzberg, Germany) was loaded per
lane on a 12.75% gel and separated by SDS-PAGE (Table S2: primary antibodies; Table S3: secondary
antibodies).
4.8. Immunohistochemical Analysis
Standard 5 µm sections of formalin-fixed and paraffin-embedded tissue blocks were used
for immunohistochemical analysis of human tissue samples (tissue microarray (TMA) comprising
specimens from benign nevi, primary melanoma and melanoma metastases) [64]. Immunohistochemical
staining was performed using an anti-HuR antibody (sc-5261, Santa Cruz, TX, USA; 1:50).
Sampling and handling of patient material were carried out in accordance with the ethical
principles of the Declaration of Helsinki. The use of human tissue material had been approved by the
local ethics committee of the University of Regensburg (application numbers 09/11 and 03/151).
4.9. Immunofluorescence Staining
Immunofluorescence analyses of cells were performed as described previously [60] (Table S2:
primary antibodies; Table S3: secondary antibodies).
4.10. Analysis of Cell Proliferation
Real-time cell proliferation was measured using the xCELLigence System (Roche, Mannheim,
Germany) (“E-Plates”) as described earlier [68]. Cell cycle analysis was performed using
fluorescence-activated cell sorting (FACS) as described [69]. Moreover, the XTT assay was used
as previously described [70].
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4.11. Clonogenic Assay
Attachment-dependent colony formation and growth of cancer cells were analyzed using
clonogenic assays as described before [71]. Both number and size of colonies were determined
using the CellSens software (Olympus, Tokio, Japan).
4.12. Analysis of Apoptosis by Flow Cytometry
Apoptotic cells were investigated by flow cytometry using the Apoptotic/Necrotic Cells Detection
Kit (PromoCell, Heidelberg, Germany) according to the manufacturer’s instructions and as described
previously [67]. The flow cytometry analysis was performed in a FACS CALIBUR cytometer (Becton
Dickinson Bioscience, Heidelberg, Germany). Flow cytometry data were analyzed using CellQuest Pro
Software (BD Bioscience).
4.13. Analysis of Intracellular ROS Content by Flow Cytometry
For analysis of ROS content, cells were washed with PBS and subsequently treated with 1 mL
2′,7′-Dichlorofluorescin diacetate (10 µM, H2DCFDA) (Sigma-Aldrich, Taufkirchen, Germany) for
15 min (37 ◦C, 8% CO2). After incubation, cells were washed with PBS, and cell pellets were collected.
Cells were suspended in PBS, and the flow cytometry analysis was performed in a FACS CALIBUR
cytometer (BD Bioscience) using the FL-1 channel. Flow cytometry data were analyzed using CellQuest
Pro Software (BD Bioscience).
4.14. Luciferase Assay
Cells were seeded in duplicates into 6-well plates and transfected, as mentioned earlier.
After 48 h, cells were transiently transfected with 0.5 µg of plasmid DNA (pSGG-empty-3′UTR,
pSGG-HuRFL-3′UTR, pGL2-basic, AP-1-LUC) using Lipofectamine Plus (Gibco, Karlsruhe, Germany)
according to the manufacturer’s instructions. The cells were lysed 24 h after transfection, and the
luciferase activity was quantified by a luminometric assay (Promega Corp., Madison, WI, USA).
To determine transfection efficiency, the data were normalized to renilla luciferase activity. Therefore,
cells were co-transfected with 0.1µg of the pRL-TK plasmid (Promega). The vectors pSGG-empty-3′UTR
and pSGG-HuRFL-3′UTR were kindly provided by Faoud Ishmael, MD [72].
4.15. Senescence-Associated ß-Galactosidase Staining
For senescence-associated ß-galactosidase staining, the Senescence ß-galactosidase Staining Kit
(Cell Signaling Technology, Danvers, MA, USA) was used in a blinded fashion as described before [67].
Cells were stained in 6-well culture plates for 24 h (melanoma cells) or 7 h (NHEMs).
4.16. Schematic Illustrations
Schematic illustrations were abstracted from “Les Laboratoires Servier—smart” Medical Art
(https://smart.servier.com/) and modified. Licensing took place according to the terms of the provider:
https://creativecommons.org/licenses/by/3.0/legalcode.
4.17. Statistical Analysis
Statistical analysis was performed using GraphPad Prism software package (GraphPad Software
Inc., San Diego, CA, USA). Results were expressed as the mean ± SEM or a percentage value.
Comparisons between groups were conducted using Student’s unpaired t-test. A p-value of <0.05
was considered statistically significant (depicted in figures as ‘*’; ns: not significant). If not depicted
otherwise in figure legends, the number of independent experiments was n ≥ 3.
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4.18. Patients’ Consent
Sampling and handling of patient material were carried out in accordance with the ethical
principles of the Declaration of Helsinki. Use of human tissue material had been approved by the local
ethics committee of the University of Regensburg (application numbers 09/11 and 03/151). For the use
of patient material without any further information with regards to the patient except for the kind of
tumor, no written individual consent is necessary in addition to the approval of the ethics committee.
HuR mRNA Level in melanoma patient tissue samples: Data obtained from publicly available sources
(GEO profiles). Survival data from skin cancer patients: Data obtained from publicly available sources
(Cancer Genome Atlas, OncoLnc, http://www.oncolnc.org [73]).
5. Conclusions
Our results show for the first time that the overexpression of HuR is an important part of the
regulatory pathway in the development of malignant melanoma and functions as a switch to overcome
or bypass oncogene-induced senescence and to support melanoma formation. These newly defined
alterations may provide possibilities for innovative therapeutic approaches.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/5/1299/s1,
Figure S1: Mean expression of mRNAs in NHEMs and primary and metastatic melanoma cells. Data from cDNA
array (Gene Omnibus (GEO) database (GSE108969)). Expression in NHEMs = 1. Expression levels of 28536 genes
were involved in the calculation, Figure S2: A Transfection control for siHuRpool and siCtrlpool transfection.
Relative expression of HuR mRNA in transfected Mel Wei and Mel Im cells (siCtrl = 1) (left). Densitometric
quantification (right) and exemplary image (middle) of western blot analysis of HuR protein levels in transfected
Mel Wei and Mel Im cells (siCtrl = 1). B Exemplary proliferation curves of Mel Wei and Mel Im cells resulting
from a XTT assay (left panel) and quantified ‘OD’ (proliferative ability, siCtrl = 1) (right panel). C FACS-based
analysis of apoptosis in transfected Mel Wei and Mel Im cells (siCtrl = 1), Figure S3: A Exemplary images of
light microscopic examination of siCtrl and siHuR transfected Mel Wei and Mel Im cells. Enlarged cells marked
with asterisks. B Exemplary images of light microscopic examination of SA-β-galactosidase staining in etoposide
treated Mel Wei and Mel Im cells (positive control) (right). The percentages of SA β galactosidase positive cells
(blue) were calculated (left) (siCtrl = 1). C Exemplary images of H3K9-trimethyl immunofluorescence staining of
Mel Wei and Mel Im cells. Panels show overlays of H3K9-trimethyl (red) and DAPI (blue) staining (left). The
graph shows the amount of H3K9-trimethyl protein (right) (siCtrl = 1), Figure S4: A Transduction control for HuR
OE. Relative expression of HuR mRNA in NHEM Mock, NHEM BrafV600E and NHEM BrafV600E/HuR OE cells
(Mock = 1). B Exemplary image of western blot analysis of HuR protein in NHEM Mock, NHEM BrafV600E and
NHEM BrafV600E/HuR OE cells (left). Densitometric quantification of HuR protein in NHEM Mock, NHEM
BrafV600E and NHEM BrafV600E/HuR OE cells (Mock = 1) (right). C Exemplary images of H3K9-trimethyl
immunofluorescence staining of NHEM Mock, NHEM BrafV600E and NHEM BrafV600E/HuR OE cells (red) and
DAPI (blue) staining. CopGFP served as a transduction control (green) (upper). The graph shows the amount of
H3K9-trimethyl protein (Mock = 1) (lower). For better recognition, colors are only shown in overlay, not in single
pictures. C The graph shows the cell count of NHEM Mock, NHEM BrafV600E and NHEM BrafV600E/HuR OE
cells one week after transduction (Mock = 1), Figure S5. The uncropped blots and molecular weight markers of
Figure 1D, Figure S6: The uncropped blots and molecular weight markers of Figure 2D, Figure S7: The uncropped
blots and molecular weight markers of Figure 3A, Figure S8: The uncropped blots and molecular weight markers of
Figure 4E, Figure S9: The uncropped blots and molecular weight markers of Figure 5C, Figure S10: The uncropped
blots and molecular weight markers of Figure 7D. Table S1: 150 randomly chosen ARE-containing mRNAs, Table
S2: List of primary antibodies, Table S3: List of secondary antibodies.
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